HUM Stock Recent News
HUM LATEST HEADLINES
Humana (HUM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rising patient volumes, technological advancements, rate hikes and other factors are likely to have benefited healthcare players during Q4. Companies like AMGN, COR, HUM and ARDT are likely to outperform.
Today's stock market has brought about a set of distracting indicators and methods to analyze a potential trade—or investment—opportunity, some of which might be accurate in a completely binary setting. What most investors fail to realize is that all of these indicators and methods rely on price action, which is why today's list cuts down all the noise to focus on one indicator alone.
Humana (HUM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Talicia is now covered by Humana's Part D Plan, providing access to Talicia for H. pylori therapy to more than eight million additional Medicare lives, without requiring prior therapeutic steps or authorization The recently updated American College of Gastroenterology (ACG) Clinical Guideline lists Talicia as a first-line option for treatment of H.
Humana (HUM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
HUM remains well-poised for growth, attributable to improved premiums, contract wins, acquisitions, collaborations and growing cash reserves.
The government's payment rate directly impacts insurers' pricing, plan benefits and overall profitability.
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Land's End, Humana, Rent the Runway, Becton, Dickinson and Company and ATI.